Management of metastatic renal cell carcinoma - mini review.

about

Solitary parotid metastasis 8 years after a nephrectomy for renal cell carcinoma Tumor suppressor microRNA-136-5p regulates the cellular function of renal cell carcinoma.

P2860

Q42396723-02F36153-8244-4207-840A-58CBFA832752 Q55225348-D43A6BDD-E1DC-475C-BF28-36DEAB3240D2

P2860

Management of metastatic renal cell carcinoma - mini review.

Item

http://www.wikidata.org/entity/Q53848926

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Management of metastatic renal cell carcinoma - mini review.

@en

Management of metastatic renal cell carcinoma - mini review.

@nl

type

Item

label

Management of metastatic renal cell carcinoma - mini review.

@en

Management of metastatic renal cell carcinoma - mini review.

@nl

prefLabel

Management of metastatic renal cell carcinoma - mini review.

@en

Management of metastatic renal cell carcinoma - mini review.

@nl

P1476

Management of metastatic renal cell carcinoma - mini review.

@en

P2093

Anubha Bharthuar

http://www.w3.org/2001/XMLSchema#string

Himanshu Pandey

http://www.w3.org/2001/XMLSchema#string

Swapan Sood

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy for advanced renal cell cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

P304

75-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15586/JKCVHL.2015.28

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276501957

http://www.w3.org/2001/XMLSchema#string

P698

28326262

http://www.w3.org/2001/XMLSchema#string

P932

5345543

http://www.w3.org/2001/XMLSchema#string

Management of metastatic renal cell carcinoma - mini review.

about

P2860

P2860

Management of metastatic renal cell carcinoma - mini review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932